Lupin informs about press release

07 Jul 2022 Evaluate

Lupin has informed that it enclosed a Press Release as regards, receipt of the Establishment Inspection Report from U.S. FDA for the Company's Somerset. NJ manufacturing facility, inspection of which was carried out in March 2022. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated. This may be considered as a disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2322.45 68.55 (3.04%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×